• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management.非小细胞肺癌患者的间质性肺疾病：病因、机制与管理
Br J Cancer. 2004 Aug;91 Suppl 2(Suppl 2):S1-2. doi: 10.1038/sj.bjc.6602060.
2
Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.克唑替尼诱发的急性间质性肺病，发生在一名EML4-ALK阳性非小细胞肺癌合并慢性间质性肺炎的患者身上。
Acta Oncol. 2014 Jan;53(1):158-60. doi: 10.3109/0284186X.2013.802838. Epub 2013 Jun 11.
3
Diagnosis and management of drug-associated interstitial lung disease.药物相关性间质性肺疾病的诊断与管理
Br J Cancer. 2004 Aug;91 Suppl 2(Suppl 2):S24-30. doi: 10.1038/sj.bjc.6602064.
4
High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.非小细胞肺癌患者中厄洛替尼高暴露与严重药物性间质性肺病
Lung Cancer. 2014 Oct;86(1):113-4. doi: 10.1016/j.lungcan.2014.07.021. Epub 2014 Aug 2.
5
The Interstitial Lung Disease-Gender-Age-Physiology Index Can Predict the Prognosis in Surgically Resected Patients with Interstitial Lung Disease and Concomitant Lung Cancer.间质肺疾病-性别-年龄-生理学指数可预测合并肺癌行手术切除的间质肺疾病患者的预后。
Respiration. 2020;99(1):9-18. doi: 10.1159/000502849. Epub 2019 Sep 25.
6
What factors determine the survival of patients with an acute exacerbation of interstitial lung disease after lung cancer resection?哪些因素决定了肺癌切除术后间质性肺疾病急性加重患者的生存情况？
Surg Today. 2018 Apr;48(4):404-415. doi: 10.1007/s00595-017-1605-8. Epub 2017 Nov 9.
7
Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.既往存在的间质性肺异常是非小细胞肺癌中免疫检查点抑制剂诱导的间质性肺病的危险因素。
Respir Investig. 2019 Sep;57(5):451-459. doi: 10.1016/j.resinv.2019.05.002. Epub 2019 Jun 24.
8
[Clinical features of acute exacerbation of interstitial pneumonia associated with lung cancer after chemotherapy].[化疗后肺癌相关性间质性肺炎急性加重的临床特征]
Gan To Kagaku Ryoho. 2009 Sep;36(9):1493-7.
9
Outcomes of curative-intent radiotherapy in non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD).有慢性阻塞性肺疾病（COPD）和间质性肺疾病（ILD）的非小细胞肺癌（NSCLC）患者接受根治性放疗的结果。
Radiother Oncol. 2021 Jul;160:78-81. doi: 10.1016/j.radonc.2021.04.014. Epub 2021 Apr 24.
10
Efficacy and tolerance of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung disease - Reply.免疫检查点抑制剂用于间质性肺疾病非小细胞肺癌患者的疗效和耐受性——回复
Respirology. 2020 Aug;25(8):892-893. doi: 10.1111/resp.13785. Epub 2020 Feb 19.

引用本文的文献

1
Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.格拉斯哥预后评分预测小细胞肺癌患者化疗诱发的急性加重性间质性肺病。
Thorac Cancer. 2021 Jun;12(11):1681-1689. doi: 10.1111/1759-7714.13900. Epub 2021 May 3.
2
Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer.非小细胞肺癌中与表皮生长因子受体酪氨酸激酶抑制剂相关不良事件的管理策略
J Adv Pract Oncol. 2016 Nov-Dec;7(7):723-735. Epub 2016 Nov 1.
3
Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures.日本吉非替尼所致间质性肺病的经验教训：审批、药物警戒及监管决策程序中的问题
Pharm Pract (Granada). 2006 Oct;4(4):168-78. doi: 10.4321/s1885-642x2006000400004.
4
Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System.用表达 ABC10 蛋白的基因治疗增强呼吸系统中的顺铂雾化化疗。
J Cancer. 2014 Mar 24;5(5):344-50. doi: 10.7150/jca.9021. eCollection 2014.
5
Six minute walking test and carbon monoxide diffusing capacity for non-small cell lung cancer: easy performed tests in every day practice.六分钟步行试验和一氧化碳弥散量在非小细胞肺癌中的应用：日常实践中易于操作的检测方法。
J Thorac Dis. 2012 Dec;4(6):569-76. doi: 10.3978/j.issn.2072-1439.2012.08.18.
6
Inhaled chemotherapy in lung cancer: future concept of nanomedicine.肺癌的吸入化疗：纳米医学的未来概念。
Int J Nanomedicine. 2012;7:1551-72. doi: 10.2147/IJN.S29997. Epub 2012 Mar 22.
7
Feasibility and effectiveness of inhaled carboplatin in NSCLC patients.吸入卡铂治疗非小细胞肺癌患者的可行性和有效性。
Invest New Drugs. 2012 Aug;30(4):1628-40. doi: 10.1007/s10637-011-9714-5. Epub 2011 Jul 8.

本文引用的文献

1
Severe acute interstitial pnuemonia and gefitinib.重症急性间质性肺炎与吉非替尼
Lung Cancer. 2004 Mar;43(3):367-8. doi: 10.1016/j.lungcan.2003.09.016.
2
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.肺癌中的表皮生长因子受体（EGFR）突变：与吉非替尼治疗临床反应的相关性
Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29.
3
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.表皮生长因子受体中的激活突变是非小细胞肺癌对吉非替尼产生反应的基础。
N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
4
Targeting targeted therapy.靶向靶向治疗。
N Engl J Med. 2004 May 20;350(21):2191-3. doi: 10.1056/NEJMe048101. Epub 2004 Apr 29.
5
Chemotherapy-induced lung disease.化疗所致肺部疾病
Clin Chest Med. 2004 Mar;25(1):53-64. doi: 10.1016/S0272-5231(03)00123-0.
6
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.吉非替尼联合紫杉醇和卡铂治疗晚期非小细胞肺癌：一项III期试验——INTACT 2
J Clin Oncol. 2004 Mar 1;22(5):785-94. doi: 10.1200/JCO.2004.07.215.
7
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.完全切除的非小细胞肺癌患者的顺铂辅助化疗。
N Engl J Med. 2004 Jan 22;350(4):351-60. doi: 10.1056/NEJMoa031644.
8
Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?化疗引起的肺部毒性：ZD1839治疗非小细胞肺癌的风险和获益如何？
Intern Med. 2003 Oct;42(10):926-7. doi: 10.2169/internalmedicine.42.926.
9
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.表皮生长因子受体酪氨酸激酶抑制剂吉非替尼在有症状的非小细胞肺癌患者中的疗效：一项随机试验。
JAMA. 2003 Oct 22;290(16):2149-58. doi: 10.1001/jama.290.16.2149.
10
Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.一名既往因吉西他滨导致溶血尿毒综合征的患者，在接受吉非替尼治疗非小细胞肺癌后出现致命性肺毒性。
Anticancer Drugs. 2003 Sep;14(8):665-8. doi: 10.1097/00001813-200309000-00014.

Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management.

作者信息

Camus P

机构信息

Services de Pneumologie, University Hospital and Medical School, Université de Bourgogne, Dijon, France.

出版信息

Br J Cancer. 2004 Aug;91 Suppl 2(Suppl 2):S1-2. doi: 10.1038/sj.bjc.6602060.

DOI:10.1038/sj.bjc.6602060
PMID:15340371
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2750812/
Abstract
摘要